search
Back to results

Impact of Antioxidant Treatment on DNA Fragmentation Index (Androferti)

Primary Purpose

Male Infertility

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Androferti
Placebo
Sponsored by
Region Skane
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Male Infertility focused on measuring sperm DNA strand breaks, antioxidants

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Referred due to infertility
  2. Age: 18-50 years,
  3. Non-smoking,
  4. Sperm DNA Fragmentation Index >25%

Exclusion Criteria:

  1. Body mass index (BMI) ≥30,
  2. FSH outside the normal range of 2-8 IU/L,g)
  3. LH outside the normal range of 2-10 IU/L,
  4. T < 10nmol/L
  5. Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
  6. History of anabolic steroids use,
  7. Taking antioxidant supplementation the last six months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Antioxidant

    Placebo

    Arm Description

    Androferti - 1 twice per day

    Placebo - 1 twice per day

    Outcomes

    Primary Outcome Measures

    DFI_3
    3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin
    DFI_6
    6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay

    Secondary Outcome Measures

    Concentration_3
    Change sperm concentration 3 months
    Concentration_6
    Change sperm concentration 6 months
    Motility_3
    Change sperm motility 3 months
    Motility_6
    Change sperm motility 6 months
    Morphology_3
    Change sperm morphology 3 months
    Morphology_6
    Change sperm morphology 6 months

    Full Information

    First Posted
    March 4, 2018
    Last Updated
    March 14, 2018
    Sponsor
    Region Skane
    Collaborators
    Q-Pharma, Octean
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03466229
    Brief Title
    Impact of Antioxidant Treatment on DNA Fragmentation Index
    Acronym
    Androferti
    Official Title
    Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    July 1, 2015 (Actual)
    Primary Completion Date
    December 31, 2016 (Actual)
    Study Completion Date
    December 31, 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Region Skane
    Collaborators
    Q-Pharma, Octean

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.
    Detailed Description
    In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant. Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities. Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient ~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis. The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome. Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting. The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options . The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Male Infertility
    Keywords
    sperm DNA strand breaks, antioxidants

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Double blind randomised placebo controlled study
    Masking
    Investigator
    Masking Description
    The active compound and placebo are given a number and the list linking this number to the type of preparation (placebo or active compound) is stored by one of the sponsors (Octean)
    Allocation
    Randomized
    Enrollment
    79 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Antioxidant
    Arm Type
    Active Comparator
    Arm Description
    Androferti - 1 twice per day
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo - 1 twice per day
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Androferti
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    DFI_3
    Description
    3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin
    Time Frame
    Change in DNA Fragmentation Index from Baseline to 3 months
    Title
    DFI_6
    Description
    6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay
    Time Frame
    Change in DNA Fragmentation Index from Baseline to 6 months
    Secondary Outcome Measure Information:
    Title
    Concentration_3
    Description
    Change sperm concentration 3 months
    Time Frame
    Change in sperm concentration from baseline to 3 months in millions/mL
    Title
    Concentration_6
    Description
    Change sperm concentration 6 months
    Time Frame
    Change in sperm concentration from baseline to 6 months in millions/mL
    Title
    Motility_3
    Description
    Change sperm motility 3 months
    Time Frame
    Change in sperm motility from baseline to 3 months in %
    Title
    Motility_6
    Description
    Change sperm motility 6 months
    Time Frame
    Change in sperm motility from baseline to 6 months in %
    Title
    Morphology_3
    Description
    Change sperm morphology 3 months
    Time Frame
    Change in sperm morphology from baseline to 3 months in %
    Title
    Morphology_6
    Description
    Change sperm morphology 6 months
    Time Frame
    Change in sperm morphology from baseline to 6 months in %

    10. Eligibility

    Sex
    Female
    Gender Based
    Yes
    Gender Eligibility Description
    Men able to deliver semen sample and investigated due to infertility
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Referred due to infertility Age: 18-50 years, Non-smoking, Sperm DNA Fragmentation Index >25% Exclusion Criteria: Body mass index (BMI) ≥30, FSH outside the normal range of 2-8 IU/L,g) LH outside the normal range of 2-10 IU/L, T < 10nmol/L Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months, History of anabolic steroids use, Taking antioxidant supplementation the last six months.

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    IPD Sharing Plan Description
    Plan to share IPD has not yet been discussed
    Citations:
    PubMed Identifier
    30298673
    Citation
    Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology. 2018 Nov;6(6):811-816. doi: 10.1111/andr.12547. Epub 2018 Oct 8.
    Results Reference
    derived

    Learn more about this trial

    Impact of Antioxidant Treatment on DNA Fragmentation Index

    We'll reach out to this number within 24 hrs